Parangi Sareh, Suh Hyunsuk
Unit of Endocrine Surgery, Massachusetts General Hospital, Harvard Medical School, Wang ACC 460, 15 Parkman Street, Boston, MA 02115, USA.
Department of General Surgery, Massachusetts General Hospital, Wang ACC 460, 15 Parkman Street, Boston, MA 02115, USA.
Surg Clin North Am. 2014 Jun;94(3):515-28. doi: 10.1016/j.suc.2014.03.001. Epub 2014 Apr 24.
Thyroid nodules are common, with increasing incidence, but only 5% to 15% of nodules are malignant. Genetic markers should only be used as an ancillary diagnostic tool for indeterminate thyroid nodules. Veracyte Afirma may improve the diagnostic accuracy for a subset of indeterminate cytologic diagnosis. Overall clinical, imaging, and cytopathologic evaluation in addition to patient preference should guide the management of indeterminate nodules. Further multicentered and independent validation studies are needed in order to prove the efficacy of commercially available genetic markers.
甲状腺结节很常见，发病率不断上升，但只有5%至15%的结节是恶性的。基因标志物仅应用作甲状腺结节性质不确定时的辅助诊断工具。Veracyte Afirma（一种检测产品）可能会提高部分性质不确定的细胞病理学诊断的诊断准确性。除了患者偏好外，综合临床、影像学和细胞病理学评估应指导性质不确定结节的管理。需要进一步开展多中心独立验证研究，以证明市售基因标志物的有效性。
